Non-criteria anti-phospholipid antibodies and cognitive impairment in SLE

Michael E. Luggen, Gaurav Gulati, Bin Zhang, Rohan A. Willis, Emilio Gonzalez

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The pathogenesis of cognitive impairment (CI) in patients with systemic lupus erythematosus (SLE) is unknown. Anti-phospholipid antibodies (APL) have been implicated. The APL which have been evaluated have variably included anti-cardiolipin (ACL) antibodies, lupus anticoagulant (LAC), and antibodies to beta-2 glycoprotein I (β2GPI). Few studies have examined other APL (so-called non-criteria APL). We evaluated the association of CI with a broad spectrum of non-criteria APL. Subjects meeting SLE classification criteria were recruited from three different patient populations. Cognitive function was assessed with the Automated Neuropsychologic Assessment Metrics (ANAM), a validated computer-based assessment tool. The total throughput score (TTS = number of correct responses/time) was used as the primary outcome measure. The following APL of all three isotypes were assessed by ELISA using standardized techniques: anti-β2GPI, anti-phosphatidyl ethanolamine (aPE), anti-phosphatidyl choline (aPC), anti-phosphatidyl inositol (aPI), anti-phosphatidyl serine (aPS), anti-phosphatidyl glycerol (aPG), anti-phosphatidic acid (aPA). Fifty-seven (57) patients were evaluated. Of the 57, 12 had definite CI (>1.5 SD below the mean of an age-, sex-, and race-matched RA population). The two groups were significantly different with regard to age, ethnicity, and family income. There was no significant difference between groups with regard to the presence of any non-criteria APL. When titers of specific non-criteria APL were compared with TTS, no significant correlations were found. Using multiple linear regression and adjusting for relevant covariates including age, ethnicity, and family income, neither the presence nor the titer of any non-criteria APL significantly influenced TTS. In this cross-sectional study, non-criteria APL were not associated with CI.

Original languageEnglish (US)
Pages (from-to)93-99
Number of pages7
JournalClinical Rheumatology
Volume35
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Systemic Lupus Erythematosus
Anti-Idiotypic Antibodies
Phospholipids
Cognitive Dysfunction
beta 2-Glycoprotein I
Lupus Coagulation Inhibitor
Phosphatidylglycerols
Phosphatidic Acids
Ethanolamine
Cardiolipins
Phosphatidylserines
Phosphatidylinositols
Phosphatidylcholines
Cognition
Population
Reaction Time
Linear Models
Glycoproteins
Cross-Sectional Studies
Enzyme-Linked Immunosorbent Assay

Keywords

  • Anti-phospholipid antibody
  • Cognitive impairment
  • SLE < Rheumatic diseases

ASJC Scopus subject areas

  • Rheumatology

Cite this

Non-criteria anti-phospholipid antibodies and cognitive impairment in SLE. / Luggen, Michael E.; Gulati, Gaurav; Zhang, Bin; Willis, Rohan A.; Gonzalez, Emilio.

In: Clinical Rheumatology, Vol. 35, No. 1, 01.01.2016, p. 93-99.

Research output: Contribution to journalArticle

Luggen, Michael E. ; Gulati, Gaurav ; Zhang, Bin ; Willis, Rohan A. ; Gonzalez, Emilio. / Non-criteria anti-phospholipid antibodies and cognitive impairment in SLE. In: Clinical Rheumatology. 2016 ; Vol. 35, No. 1. pp. 93-99.
@article{3d395e52c96c4346bf5c55588f51a62a,
title = "Non-criteria anti-phospholipid antibodies and cognitive impairment in SLE",
abstract = "The pathogenesis of cognitive impairment (CI) in patients with systemic lupus erythematosus (SLE) is unknown. Anti-phospholipid antibodies (APL) have been implicated. The APL which have been evaluated have variably included anti-cardiolipin (ACL) antibodies, lupus anticoagulant (LAC), and antibodies to beta-2 glycoprotein I (β2GPI). Few studies have examined other APL (so-called non-criteria APL). We evaluated the association of CI with a broad spectrum of non-criteria APL. Subjects meeting SLE classification criteria were recruited from three different patient populations. Cognitive function was assessed with the Automated Neuropsychologic Assessment Metrics (ANAM), a validated computer-based assessment tool. The total throughput score (TTS = number of correct responses/time) was used as the primary outcome measure. The following APL of all three isotypes were assessed by ELISA using standardized techniques: anti-β2GPI, anti-phosphatidyl ethanolamine (aPE), anti-phosphatidyl choline (aPC), anti-phosphatidyl inositol (aPI), anti-phosphatidyl serine (aPS), anti-phosphatidyl glycerol (aPG), anti-phosphatidic acid (aPA). Fifty-seven (57) patients were evaluated. Of the 57, 12 had definite CI (>1.5 SD below the mean of an age-, sex-, and race-matched RA population). The two groups were significantly different with regard to age, ethnicity, and family income. There was no significant difference between groups with regard to the presence of any non-criteria APL. When titers of specific non-criteria APL were compared with TTS, no significant correlations were found. Using multiple linear regression and adjusting for relevant covariates including age, ethnicity, and family income, neither the presence nor the titer of any non-criteria APL significantly influenced TTS. In this cross-sectional study, non-criteria APL were not associated with CI.",
keywords = "Anti-phospholipid antibody, Cognitive impairment, SLE < Rheumatic diseases",
author = "Luggen, {Michael E.} and Gaurav Gulati and Bin Zhang and Willis, {Rohan A.} and Emilio Gonzalez",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/s10067-015-3114-8",
language = "English (US)",
volume = "35",
pages = "93--99",
journal = "Clinical Rheumatology",
issn = "0770-3198",
publisher = "Springer London",
number = "1",

}

TY - JOUR

T1 - Non-criteria anti-phospholipid antibodies and cognitive impairment in SLE

AU - Luggen, Michael E.

AU - Gulati, Gaurav

AU - Zhang, Bin

AU - Willis, Rohan A.

AU - Gonzalez, Emilio

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The pathogenesis of cognitive impairment (CI) in patients with systemic lupus erythematosus (SLE) is unknown. Anti-phospholipid antibodies (APL) have been implicated. The APL which have been evaluated have variably included anti-cardiolipin (ACL) antibodies, lupus anticoagulant (LAC), and antibodies to beta-2 glycoprotein I (β2GPI). Few studies have examined other APL (so-called non-criteria APL). We evaluated the association of CI with a broad spectrum of non-criteria APL. Subjects meeting SLE classification criteria were recruited from three different patient populations. Cognitive function was assessed with the Automated Neuropsychologic Assessment Metrics (ANAM), a validated computer-based assessment tool. The total throughput score (TTS = number of correct responses/time) was used as the primary outcome measure. The following APL of all three isotypes were assessed by ELISA using standardized techniques: anti-β2GPI, anti-phosphatidyl ethanolamine (aPE), anti-phosphatidyl choline (aPC), anti-phosphatidyl inositol (aPI), anti-phosphatidyl serine (aPS), anti-phosphatidyl glycerol (aPG), anti-phosphatidic acid (aPA). Fifty-seven (57) patients were evaluated. Of the 57, 12 had definite CI (>1.5 SD below the mean of an age-, sex-, and race-matched RA population). The two groups were significantly different with regard to age, ethnicity, and family income. There was no significant difference between groups with regard to the presence of any non-criteria APL. When titers of specific non-criteria APL were compared with TTS, no significant correlations were found. Using multiple linear regression and adjusting for relevant covariates including age, ethnicity, and family income, neither the presence nor the titer of any non-criteria APL significantly influenced TTS. In this cross-sectional study, non-criteria APL were not associated with CI.

AB - The pathogenesis of cognitive impairment (CI) in patients with systemic lupus erythematosus (SLE) is unknown. Anti-phospholipid antibodies (APL) have been implicated. The APL which have been evaluated have variably included anti-cardiolipin (ACL) antibodies, lupus anticoagulant (LAC), and antibodies to beta-2 glycoprotein I (β2GPI). Few studies have examined other APL (so-called non-criteria APL). We evaluated the association of CI with a broad spectrum of non-criteria APL. Subjects meeting SLE classification criteria were recruited from three different patient populations. Cognitive function was assessed with the Automated Neuropsychologic Assessment Metrics (ANAM), a validated computer-based assessment tool. The total throughput score (TTS = number of correct responses/time) was used as the primary outcome measure. The following APL of all three isotypes were assessed by ELISA using standardized techniques: anti-β2GPI, anti-phosphatidyl ethanolamine (aPE), anti-phosphatidyl choline (aPC), anti-phosphatidyl inositol (aPI), anti-phosphatidyl serine (aPS), anti-phosphatidyl glycerol (aPG), anti-phosphatidic acid (aPA). Fifty-seven (57) patients were evaluated. Of the 57, 12 had definite CI (>1.5 SD below the mean of an age-, sex-, and race-matched RA population). The two groups were significantly different with regard to age, ethnicity, and family income. There was no significant difference between groups with regard to the presence of any non-criteria APL. When titers of specific non-criteria APL were compared with TTS, no significant correlations were found. Using multiple linear regression and adjusting for relevant covariates including age, ethnicity, and family income, neither the presence nor the titer of any non-criteria APL significantly influenced TTS. In this cross-sectional study, non-criteria APL were not associated with CI.

KW - Anti-phospholipid antibody

KW - Cognitive impairment

KW - SLE < Rheumatic diseases

UR - http://www.scopus.com/inward/record.url?scp=84954375576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954375576&partnerID=8YFLogxK

U2 - 10.1007/s10067-015-3114-8

DO - 10.1007/s10067-015-3114-8

M3 - Article

C2 - 26563139

AN - SCOPUS:84954375576

VL - 35

SP - 93

EP - 99

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 0770-3198

IS - 1

ER -